RT Journal Article
SR Electronic
T1 Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.09.21267513
DO 10.1101/2021.12.09.21267513
A1 Marconato, Maddalena
A1 Abela, Irene A.
A1 Hauser, Anthony
A1 Schwarzmüller, Magdalena
A1 Katzensteiner, Rheliana
A1 Braun, Dominique L.
A1 Epp, Selina
A1 Audigé, Annette
A1 Weber, Jacqueline
A1 Rusert, Peter
A1 Schindler, Emèry
A1 Pasin, Chloé
A1 West, Emily
A1 Böni, Jürg
A1 Kufner, Verena
A1 Huber, Michael
A1 Zaheri, Maryam
A1 Schmutz, Stefan
A1 Frey, Beat M.
A1 Kouyos, Roger D.
A1 Günthard, Huldrych F.
A1 Manz, Markus G.
A1 Trkola, Alexandra
YR 2021
UL http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267513.abstract
AB Neutralizing antibodies are considered a key correlate of protection by current SARS-CoV-2 vaccines. The ability of antibody-based therapies, including convalescent plasma, to affect established disease remains to be elucidated. Only few monoclonal therapies and only when used at a very early stage of infection have shown efficacy. Here, we conducted a proof-of-principle study of convalescent plasma therapy in a phase I trial in 30 COVID-19 patients including immunocompromised individuals hospitalized early after onset of symptoms. A comprehensive longitudinal monitoring of the virologic, serologic, and disease status of recipients in conjunction with detailed post-hoc seroprofiling of transfused convalescent plasma, allowed deciphering of parameters on which plasma therapy efficacy depends. Plasma therapy was safe and had a significant effect on viral clearance depending on neutralizing and spike SARS-CoV-2 antibody levels in the supplied convalescent plasma. Endogenous immunity had strong effects on virus control. Lack of endogenous neutralizing activity at baseline was associated with a higher risk of systemic viremia. The onset of endogenous neutralization had a noticeable effect on viral clearance but, importantly, even after adjusting for their endogenous neutralization status recipients benefitted from therapy with high neutralizing antibody containing plasma.In summary, our data demonstrate a clear impact of exogenous antibody therapy on the rapid clearance of viremia in the early stages of infection and provide directions for improved efficacy evaluation of current and future SARS-CoV-2 therapies beyond antibody-based interventions. Incorporating an assessment of the endogenous immune response and its dynamic interplay with viral production is critical for determining therapeutic effects.One Sentence Summary This study demonstrates the impact of exogenous antibody therapy by convalescent plasma containing high neutralizing titers on the rapid clearance of viremia in the early stages of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04869072Funding StatementThis study was funded via an Innovation-Pool project by the University Hospital Zurich and via the Swiss Red Cross Glueckskette Corona Funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was initiated in April 2020 and completed in November 2020 and was approved by the local ethics committee of the Canton of Zurich, Switzerland, Kantonale Ethikkommission, Zurich (KEK). Approval number BASEC 2020-00787 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors